# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K082329   
B. Purpose for Submission: To obtain a Substantial Equivalence determination for a new d   
C. Measurand: IgM antibodies to Borrelia burgdorferi (B. burgdorferi)   
D. Type of Test: Line blot assay   
E. Applicant: Viramed Biotech AG   
F. Proprietary and Established Names: Borrelia B31 IgM ViraStripe®

# G. Regulatory Information:

1. Regulation section: 21 CFR 866. 3830, Treponema pallidum treponemal test reagents

2. Classification: Class: II

3. Product code: LSR; Reagent, Borrelia Serological Reagent

4. Panel: 83- Microbiology

# H. Intended Use:

1. Intended use(s):

The Viramed Biotech AG Borrelia $\mathrm { B } 3 1 \ \mathrm { I g M }$ ViraStripe® is an in vitro qualitative assay for the detection of IgM antibodies against Borrelia burgdorferi in human serum. It is intended for use in the testing of human serum samples which have been found positive or equivocal using an EIA or IFA test procedure for $B$ . burgdorferi antibodies.

# 2. Indication(s) for use:

The Viramed Biotech AG Borrelia B31 IgM ViraStripe® is an in vitro qualitative assay for the detection of IgM antibodies against Borrelia burgdorferi in human serum. It is intended for use in the testing of human serum samples which have been found positive or equivocal using an EIA or IFA test procedure for $B$ . burgdorferi antibodies. Positive results from this line blot assay are supportive evidence of infection with $B _ { \cdot }$ . burgdorferi, the causative agent for Lyme disease. The Viramed Biotech AG Borrelia B31 IgM ViraStripe® can be used during the acute phase (0-4 weeks of symptoms onset) of B. burgdorferi infection. Patients who are positive by $\mathrm { I g M }$ but not IgG should have the test repeated a few weeks later if they remain ill. If they are still positive only by IgM and have been ill longer than one month, this is likely a false positive.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: None

# I. Device Description:

The Viramed Biotech AG Borrelia B31 IgM ViraStripe® is a line blot assay to detect IgM to individual B. burgdorferi antigens. Isolated cultures of $B$ . burgdorferi B31 spirochetes were harvested, concentrated, washed, and extracted to produce antigen fractions. Antigens were purified by electrophoretic and chromatographic methodologies and line striped on a nitrocellulose membrane. B. burgdorferi antigens are bound and fixed to the solid phase nitrocellulose membrane. The membrane is blocked, dried and cut into individual test strips.

For each test to be performed, the line blot strip and diluted test serum is added to a line blot strip well. If specific antibodies that recognize an antigen are present, they will bind to the specific antigens on the strip. After incubation the line blot strip is washed to remove unbound antibodies. Alkaline-phosphatase anti-human IgM conjugate is then added to each strip and incubated. If antibody is present, the conjugate will bind to the antibody attached to the specific antigens. The strip is washed to remove unbound conjugate and the substrate solution is added. If the enzyme/antibody complex is present, the substrate will undergo a precipitation and color change. After an incubation period, the reaction is stopped and the presence of precipitated substrate is visualized at specific locations on the strip. The presence of a colored precipitation at various locations on the line blot strip is an indirect measurement of Borrelia burgdorferi specific antibodies in the patient specimen. A uniform band locator is given on the evaluation protocol and used to locate and identify specific Borrelia burgdorferi B31 antibodies on the line blot test strip. Every strip has an integrated control system including function control and conjugate control. Visualized bands from the reaction are compared for intensity with a separate strip containing the Cut-off control band for evaluation. Any band found having a visual intensity equal to or greater than the Cut-off control band intensity is considered as a significant band.

Positivity: The criteria for a positive Western blot result defined by the CDC are followed. For $B _ { \cdot }$ . burgdorferi IgM positivity, the blot should be positive for at least 2 of the 3 protein bands: p41, p39, p23kDa

# J. Substantial Equivalence Information:

1. Predicate device name(s): Viramed Biotech AG Borrelia B31 IgM ViraBlot

2. Predicate 510(k) number(s): K051169

3. Comparison with predicate:

<table><tr><td colspan="3">Similarities</td></tr><tr><td>Item</td><td>Device</td><td>Predicate</td></tr><tr><td>Intended Use</td><td>The Viramed Biotech AG Borrelia B31 IgM ViraStripe® is an in vitro ® qualitative assay for the detection of IgM antibodies against Borrelia burgdorferi in human serum. It is intended for use in the testing of human serum samples which have been</td><td>The Viramed Biotech Borrelia B31 IgM ViraBlot® is an in vitro qualitative assay for the detection of IgM antibodies to Borrelia burgdorferi in human serum. It is intended for use in testing human serum samples which have been found positive or</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">found positive or equivocalusing an EIA or IFA testprocedure for B.burgdorferi antibodies.</td><td colspan="1" rowspan="1">equivocal using an EIA orIFA test procedure for B.burgdorferi antibodies.</td></tr><tr><td colspan="1" rowspan="1">Assay</td><td colspan="1" rowspan="1">Line blot</td><td colspan="1" rowspan="1">Line blot</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="2" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Procedure</td><td colspan="1" rowspan="1">Qualitative; B. burgdorferiIgM antibodies to specificprotein bands for theelution, purification andconcentration of themembrane proteins</td><td colspan="1" rowspan="1">Qualitative; B. burgdorferiIgM antibodies to specificprotein bands.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline—Second Edition and CLSI M34-A, Western Blot Assay for Antibodies to Borrelia burgdorferi, Approved Guidance

L. Test Principle: Line blot

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Eight serum samples (low negative, high negative, low positive and moderate positive) were tested in duplicate over 5 working days (twice) by separate technicians at three laboratory sites using the same kit lot number. The serum panel specimens were selected to represent negative to high-positive immune-reactivity levels. For this study, two different readers within the three different laboratories assessed the band identification for each sample on the same blot. Six qualified technicians at the three sites assessed the Western blot bands from the same master lot kit number of Western blot kit. All samples were correctly interpreted by the 3 laboratories and 6 readers with $100 \%$ concordance for IgM.

<table><tr><td rowspan=1 colspan=1>StudySummary</td><td rowspan=1 colspan=4>Day 1- 5</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>Sample ID</td><td rowspan=1 colspan=2>Tech 1</td><td rowspan=1 colspan=2>Tech 2</td><td rowspan=1 colspan=1>AllTechnicians</td></tr><tr><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>Agreement</td></tr><tr><td rowspan=1 colspan=1>Low negative</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>High negative(1)</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>39</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>High negative(2)</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Low Positive(11)</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Low Positive (2)</td><td rowspan=1 colspan=1>41,39,23</td><td rowspan=1 colspan=1>41,39,23</td><td rowspan=1 colspan=1>41,39,23</td><td rowspan=1 colspan=1>41,39,23</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Low Positive (3)</td><td rowspan=1 colspan=1>39,23</td><td rowspan=1 colspan=1>39,23</td><td rowspan=1 colspan=1>39,23</td><td rowspan=1 colspan=1>39,23</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>ModeratePositive (1)</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>ModeratePositive (2)</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>41,23</td><td rowspan=1 colspan=1>100%</td></tr></table>

The Reproducibility study was satisfactory for this type of assay.

b. Linearity/assay reportable range: Not applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not applicable   
d. Detection limit: Not applicable   
e. Analytical specificity:

# Cross-Reactivity

Seventy-five sera determined to contain antibodies to other infectious disease agents were tested. Cross-reactivity data for Ehrlichia chafeensis and Babesia microti may represent an actual co-infection with $B .$ . burgdorferi. All three tick borne organisms have been found to reside in the geographic location from which these 15 clinical specimens were obtained. Both of the specimens found positive in the Viramed Biotech AG Borrelia B31 IgM ViraStripe® were also found to be positive in a commercially available Lyme Western blot test system. Potential cross-reactivity due to circulating antibodies from infections with Treponema phagedenis, Neisseria meningitidis, Haemophilus influenza, Yersinia enterocolitica, Campylobacter jejuni, Listeria monocytogenes, Pseudomonas aeruginosa, $E$ . coli, Salmonella enterica serovar typhimurium, Shigella flexneri, and Legionella micdadei have not been challenged, therefore the performance of this device is unknown if the specimen contains any of these circulating antibodies. See the Limitations section of the package insert for a list of untested, potentially cross-reactive organisms.

<table><tr><td rowspan=1 colspan=1>Disease State Sera</td><td rowspan=1 colspan=1>Number</td><td rowspan=1 colspan=1>Borrelia B31 IgMViraStripe® Positive</td><td rowspan=1 colspan=1>Percent cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>Ehrlichiachaffeensis</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Babesia microti</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Borrelia hermsii</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>33%</td></tr><tr><td rowspan=1 colspan=1>Leptospirainterrogans</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Helicobacter pylori</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>ENA Autoimmune</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>Treponemapallidum</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td></tr></table>

# INTERFERING SUBSTANCES

The following substances had an effect on test results when present in sera: hemolyzed, lipemic, or icteric sera and should not be used for testing. Because the firm did not test any sera from patients with immune-deficient diseases, elevated bilirubin, triglycerides, and heat-inactivated sera, the following statements will be added to the package insert: “The performance of this assay when testing sera from patients with any immune-deficient diseases such as HIV, HTLV, etc. and sera from patients that have had immunesuppressive therapy with drugs or medications is not known because no studies were conducted to assess the performance. Do not use heatinactivated sera. Sera with elevated bilirubin, and triglycerides were not tested.

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

Correlations to the CDC Lyme Disease Panel

A Lyme Disease Clinical panel containing 44 clinically defined positives and negative samples was obtained from the Center for Disease Control and Prevention, Fort Collins, Colorado.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>Borrelia B31 IgM ViraStripe</td></tr><tr><td rowspan=1 colspan=1>Time after Onset</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>%Agreement</td></tr><tr><td rowspan=1 colspan=1>Normals</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Clinically Undefined</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Early Localized</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>85%</td></tr><tr><td rowspan=1 colspan=1>Disseminated Disease</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>89%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>89%</td></tr></table>

# College of American Pathologists 2003 Tick-borne Disease Proficiency Panel

The CAP Tick-borne Proficiency samples for the year 2003 were tested.

Samples tested: Positive 2 Negative 13 Correlation to Published CAP results proficiency $= 9 3 \%$ (14/15)

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Sensitivity:

A total of 436 samples were prospectively collected and found to be EIA positive were sent to laboratories in California, Wisconsin, and Minnesota for Lyme disease testing. Samples were tested with the Viramed Biotech AG Borrelia B31 IgM ViraStripe® and the predicate. Results are presented in the tables below.

Subjects Sent to the Laboratory for Lyme Disease Testing   

<table><tr><td rowspan=2 colspan=1>Predicate</td><td rowspan=1 colspan=2>Borrelia B31 IgM ViraStripe®</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>370</td><td rowspan=1 colspan=1>374</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>377</td><td rowspan=1 colspan=1>436</td></tr></table>

<table><tr><td rowspan=1 colspan=2>Percent Agreement</td><td rowspan=1 colspan=1>Exact 95% Confidence Intervals</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>88.7%     (55/62)</td><td rowspan=1 colspan=1>(78.1% - 95.3%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>98.9%  (370/374)</td><td rowspan=1 colspan=1>(97.3% - 99.7%)</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>97.5% (425/436)</td><td rowspan=1 colspan=1>(95.5% - 98.7%)</td></tr></table>

One hundred and eighty five sera were obtained from patients that were clinically defined (culture confirmed) with Lyme borreliosis. Of these 185 sera, 158 were paired (79 acute and 79 convalescent) sera from patients diagnosed with Erythema migrans (EM), 11 with early-disseminated Lyme Disease/Carditis/Acute Neuroborreliosis and 16 with late stage Lyme arthritis. These samples were tested with the Borrelia $\mathrm { B } 3 1 \ \mathrm { I g M }$ ViraStripe® and the predicated. Results are presented in the tables below.

# Clinically-defined Lyme disease samples

<table><tr><td rowspan=2 colspan=1>Stage</td><td rowspan=1 colspan=4>Borrelia B31 IgM ViraStripe®</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Sensitivity (95% Confidence Intervals)</td></tr><tr><td rowspan=1 colspan=1>Acute EM1-21 days from Onset</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>38% (27.3% - 49.6%)</td></tr><tr><td rowspan=1 colspan=1>Convalescent EM4 weeks after Onset</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>67% (55.6% - 77.3%)</td></tr><tr><td rowspan=1 colspan=1>Early Neurologic</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>82% (48.2%  97.7%)</td></tr><tr><td rowspan=1 colspan=1>Late Arthritis</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>38% (15.2%  64.6%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1></td></tr></table>

<table><tr><td rowspan=2 colspan=1>Borrelia B31 ViraBlot® IgM</td><td rowspan=1 colspan=3>Borrelia B31 IgM ViraStripe®</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>106</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>79</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>87</td><td rowspan=1 colspan=1>185</td></tr></table>

<table><tr><td rowspan=1 colspan=1>EY</td><td rowspan=1 colspan=1>Percent Agreement</td><td rowspan=1 colspan=1>95% Confidence Intervals</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>92.8% (91/98)</td><td rowspan=1 colspan=1>85.8% - 97.1%</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>82.7% (72/87)</td><td rowspan=1 colspan=1>73.2% - 90.0%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>88.1% (163/185)</td><td rowspan=1 colspan=1>83.4% - 92.8%</td></tr></table>

# b. Clinical specificity:

For determination of analytical specificity, two hundred of the sera from normal blood donor individuals representing endemic and non-endemic geographic regions of the United States were tested for IgM Borrelia burgdorferi antibodies by the Viramed Biotech AG Borrelia $\mathrm { B } 3 1 \ \mathrm { I g M }$ ViraStripe® - see table below:

# Analytical Specificity

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>Endemic</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2%</td></tr><tr><td rowspan=1 colspan=1>Non-endemic</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1%</td></tr></table>

c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.